Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$110.45 USD

110.45
389,055

+0.42 (0.38%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.

STERIS (STE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.

JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised

by Zacks Equity Research

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.

Jazz Pharmaceuticals (JAZZ) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -0.53% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q1 Earnings Expected to Decline

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

by Zacks Equity Research

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon

by Zacks Equity Research

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

JAZZ Inks Deal With Werewolf to Add Oncology Candidate

by Zacks Equity Research

Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.

Jazz (JAZZ) Up 2.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More

by Zacks Equity Research

Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.

Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi

by Zacks Equity Research

Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.

JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors

by Zacks Equity Research

JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.

Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs

by Zacks Equity Research

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates

by Zacks Equity Research

ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.

Kinjel Shah headshot

Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More

by Kinjel Shah

Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.

Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Jazz Pharmaceuticals (JAZZ) Stock a Suitable Value Pick Now?

by Zacks Equity Research

Let's see if Jazz Pharmaceuticals plc (JAZZ) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Ekta Bagri headshot

4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates

by Ekta Bagri

Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.